Safety of the electroconvulsive therapy-ziprasidone combination

Journal of ECT

Volumn 26, Issue 2, 2010, Pages 139-142

  Masdrakis, Vasilios G ^a   Florakis, Andreas ^a   Tzanoulinos, Georgios ^a   Markatou, Maria ^a   Oulis, Panagiotis ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; LEVOMEPROMAZINE; LEVOTHYROXINE; MIRTAZAPINE; MODAFINIL; PINDOLOL; PROPRANOLOL; QUETIAPINE; VENLAFAXINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; ELECTROCONVULSIVE THERAPY; FEMALE; HEADACHE; HUMAN; MAJOR DEPRESSION; MEMORY DISORDER; MYALGIA; PARANOID SCHIZOPHRENIA; QT INTERVAL; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MIDDLE AGED; PIPERAZINES; THIAZOLES;

EID: 77953129860     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e3181c1880e     Document Type: Article

References (36)

1. McCall WV. Electroconvulsive therapy in the era of modern psychopharmacology. Int J Neuropsychopharmacol. 2001;4:315-324.
2. Datto CJ. Side effects of electroconvulsive therapy. Depress Anxiety. 2000;12:130-134.
3. Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT. 2005;21:75-83.
4. Nothdurfter C, Eser D, Schüle C, et al. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry. 2006;7:162-170. (Pubitemid 44132542)
5. Painuly N, Chakrabarti S. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis. J ECT. 2006;22:59-66.
6. Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry. 2007;20:23-29.
7. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol. 2008;11:999-1029.
8. Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
9. Arango C, Gomez-Beneyto M, Brenlla J, et al. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Eur Neuropsychopharmacol. 2007;17:456-463.
10. Kudla D, Lambert M, Domin S. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry. 2007;22:195-202.
11. Ratner Y, Gibel A, Yorkov V, et al. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1401-1409. (Pubitemid 47302551)
12. Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol Bull. 2001;35:66-79.
13. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62:1649-1671.
14. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs. 2003;17:423-430.
15. Eker SS, Sarandol A, Akkaya C, et al. The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases. J Psychopharmacol. 2009;23:993-996.
16. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q. 2003;74:291-306.
17. Simpson GM, O'Gorman CJ, Loebel A, et al. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. CNS Spectr. 2008;13:898-905.
18. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
19. Zervas IM, Papakostas YG, Theodoropoulou MA, et al. Thyrotropin-releasing hormone administration does not affect seizure threshold during electroconvulsive therapy. J ECT. 2003;19:136-138.
20. Petrides G, Fink M. The "half-age' stimulation strategy for ECT dosing. Convuls Ther. 1996;12:138-146.
21. Folstein MF, Folstein SE, McHugh PR. " Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
22. Tang WK, Ungvari GS. Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial. J ECT. 2002;18:90-94.
23. Gazdag G, Barna I, Ivanyi Z, et al. The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy. Ideggyogy Sz. 2004;57:385-390.
24. Tan QR, Wang W, Wang HH, et al. Treatment of catatonic stupor with combination of modified electroconvulsive treatment and olanzapine: a case report. Clin Neuropharmacol. 2006;29:154-156.
25. Dew RE, Rosenquist PB, McCall WV. Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. Int J Adolesc Med Health. 2005;17:187-188.
26. Masdrakis VG, Oulis P, Zervas IM, et al. The safety of the electroconvulsive therapy-aripiprazole combination: four case reports. J ECT. 2008;24:236-238.
27. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded assessment study. Psychopharmacology. 2005;178:514-523.
28. Olie JP, Spina E, Murray S, et al. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol. 2006;21:143-151.
29. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.
30. Papakostas GI, Peterson TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217-221.
31. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005a;66(suppl 8):13-21.
32. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 2005b; 10:1-20.
33. Mech AW. High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes. J Clin Psychopharmacol. 2008;28:240-241.
34. Lublin H, Haug H-J, Koponen H, et al. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry. 2008;19:1-9.
35. Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract. 2004;10:227-232.
36. Gomez-Criado MS, Bernardo M, Florez T, et al. Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. Pharmacotherapy. 2005;25:1660-1665.